Buyers search development shares to capitalize on above-average development in financials that assist these securities seize the market’s consideration and produce distinctive returns. However discovering a fantastic development inventory will not be straightforward in any respect.
That is as a result of, these shares often carry above-average threat and volatility. In truth, betting on a inventory for which the expansion story is definitely over or nearing its finish may result in vital loss.
Nevertheless, it is fairly straightforward to search out cutting-edge development shares with the assistance of the Zacks Progress Type Rating (a part of the Zacks Style Scores system), which appears past the normal development attributes to investigate an organization’s actual development prospects.
Penumbra (PEN) is one such inventory that our proprietary system presently recommends. The corporate not solely has a good Progress Rating, but in addition carries a prime Zacks Rank.
Analysis exhibits that shares carrying the very best development options constantly beat the market. And for shares which have a mixture of a Progress Rating of A or B and a Zacks Rank #1 (Sturdy Purchase) or 2 (Purchase), returns are even higher.
Listed below are three of a very powerful elements that make the inventory of this medical system maker a fantastic development decide proper now.
Earnings Progress
Earnings development is arguably a very powerful issue, as shares exhibiting exceptionally surging revenue ranges have a tendency to draw the eye of most traders. And for development traders, double-digit earnings development is certainly preferable, and infrequently a sign of sturdy prospects (and inventory value positive aspects) for the corporate into consideration.
Whereas the historic EPS development price for Penumbra is 38.8%, traders ought to truly give attention to the projected development. The corporate’s EPS is predicted to develop 34.4% this 12 months, crushing the business common, which requires EPS development of 15.4%.
Money Stream Progress
Whereas money is the lifeblood of any enterprise, higher-than-average money circulation development is extra necessary and helpful for growth-oriented firms than for mature firms. That is as a result of, development in money circulation permits these firms to increase their companies with out relying on costly exterior funds.
Proper now, year-over-year money circulation development for Penumbra is 255.5%, which is greater than a lot of its friends. In truth, the speed compares to the business common of -4.9%.
Whereas traders ought to truly think about the present money circulation development, it is price having a look on the historic price too for placing the present studying into correct perspective. The corporate’s annualized money circulation development price has been 34.6% over the previous 3-5 years versus the business common of 5.5%.
Promising Earnings Estimate Revisions
Superiority of a inventory by way of the metrics outlined above could be additional validated by wanting on the development in earnings estimate revisions. A optimistic development is after all favorable right here. Empirical analysis exhibits that there’s a sturdy correlation between tendencies in earnings estimate revisions and near-term inventory value actions.
The present-year earnings estimates for Penumbra have been revising upward. The Zacks Consensus Estimate for the present 12 months has surged 0.6% over the previous month.
Backside Line
Whereas the general earnings estimate revisions have made Penumbra a Zacks Rank #2 inventory, it has earned itself a Progress Rating of A primarily based on quite a few elements, together with those mentioned above.
You may see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
This mix positions Penumbra nicely for outperformance, so development traders might need to guess on it.
Zacks Naming Prime 10 Shares for 2025
Need to be tipped off early to our 10 prime picks for everything of 2025?
Historical past suggests their efficiency could possibly be sensational.
From 2012 (when our Director of Analysis Sheraz Mian assumed duty for the portfolio) by way of November, 2024, the Zacks Prime 10 Shares gained +2,112.6%, greater than QUADRUPLING the S&P 500’s +475.6%. Now Sheraz is combing by way of 4,400 firms to handpick the very best 10 tickers to purchase and maintain in 2025. Don’t miss your probability to get in on these shares after they’re launched on January 2.
Be First to New Top 10 Stocks >>
Penumbra, Inc. (PEN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.
